OYST · Oyster Point Pharma, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|
| Revenue | $0 | - | - |
| Cost of Revenue | $0 | - | - |
| Gross Profit | $0 | - | - |
| R&D | $24.23M | $39.81M | $13.76M |
| SG&A | $40.81M | $31.18M | $2.98M |
| Total Operating Expenses | $119.67M | $70.99M | $16.74M |
| D&A | $141.0K | $77.0K | $0 |
| Operating Income | ($96.66M) | ($70.99M) | ($16.74M) |
| Interest Expense | $0 | - | - |
| Income Tax | $0 | $0 | $0 |
| Net Income | ($100.66M) | ($70.52M) | ($16.50M) |
| EPS - Basic | ($2.92) | - | - |
| EPS - Diluted | ($2.92) | - | - |
Balance Sheet
| Line item | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|
| Cash & Equivalents | $193.37M | $192.59M | $139.15M |
| Accounts Receivable | $0 | - | - |
| Inventory | $0 | - | - |
| Accounts Payable | $6.50M | $2.28M | $500.0K |
| Current Assets | $215.25M | $196.37M | $142.18M |
| Total Assets | $222.62M | $197.91M | $143.21M |
| Current Liabilities | $28.80M | $10.98M | $5.40M |
| Long-term Debt | $89.81M | - | - |
| Total Liabilities | $123.08M | $11.25M | $5.91M |
| Stockholders' Equity | $99.54M | $186.66M | $137.30M |
| Retained Earnings | ($255.41M) | ($154.75M) | ($84.23M) |
Cash Flow
| Line item | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|
| Operating Cash Flow | ($89.37M) | ($58.40M) | ($17.08M) |
| Investing Cash Flow | ($1.49M) | ($700.0K) | $0 |
| Financing Cash Flow | $91.64M | $112.55M | $0 |
| CapEx | $1.49M | $700.0K | $0 |
| Free Cash Flow | ($90.86M) | ($59.10M) | ($17.08M) |
Ratios
| Metric | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|
| Profitability | |||
| Gross margin | - | - | - |
| Operating margin | - | - | - |
| EBITDA margin | - | - | - |
| Net margin | - | - | - |
| Free cash flow margin | - | - | - |
| FCF / Net income | 0.90 | 0.84 | 1.04 |
| R&D / Revenue | - | - | - |
| SG&A / Revenue | - | - | - |
| Effective tax rate | - | - | - |
| Return on assets | -45.2% | -35.6% | -11.5% |
| Return on equity | -101.1% | -37.8% | -12.0% |
| Return on invested capital | -40.3% | - | - |
| Liquidity | |||
| Current ratio | 7.47 | 17.88 | 26.33 |
| Quick ratio | 7.47 | 17.88 | 26.33 |
| Cash ratio | 6.71 | 17.54 | 25.77 |
| Leverage | |||
| Debt / Equity | 0.90 | - | - |
| Debt / Assets | 0.40 | - | - |
| Debt / EBITDA | - | - | - |
| Interest coverage | - | - | - |
| Equity multiplier | 2.24 | 1.06 | 1.04 |
| Liabilities / Assets | 0.55 | 0.06 | 0.04 |
| Efficiency | |||
| Asset turnover | 0.00 | - | - |
| Inventory turnover | - | - | - |
| Days sales outstanding | - | - | - |
| Days inventory outstanding | - | - | - |
| Days payable outstanding | - | - | - |
| Cash conversion cycle | - | - | - |
| Valuation | |||
| P / E | - | - | - |
| P / B | - | - | - |
| P / S | - | - | - |
| EV / EBITDA | - | - | - |
| Growth | |||
| Revenue growth (YoY) | - | - | - |
| Revenue CAGR (3y) | - | - | - |
| Revenue CAGR (5y) | - | - | - |
| Gross profit growth (YoY) | - | - | - |
| Operating income growth (YoY) | -36.2% | -324.2% | - |
| Net income growth (YoY) | -42.7% | -327.3% | - |
| EPS growth (YoY) | - | - | - |
| EPS CAGR (3y) | - | - | - |
| EPS CAGR (5y) | - | - | - |
| FCF growth (YoY) | -53.7% | -246.0% | - |
| FCF CAGR (5y) | - | - | - |
| Book value growth (YoY) | -46.7% | 36.0% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$25.74M totalLicense$18.39M · 71.4%
Milestone Revenue$5.00M · 19.4%
TYRVAYANasal Spray$1.20M · 4.7%
Product$1.15M · 4.5%
Stability scores
Altman Z′
FY 2021 · bankruptcy risk
-1.38
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2021 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- -No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Oyster Point Pharma against the 5 most active filers in the same SIC group.